Dow Jones biotech giant Amgen stock is trading in a buy zone following its recent breakout move amid the ongoing market weakness.
Amgen unveiled test results Wednesday that suggest it could have one of the first immune-modulating treatments for Sjogren's.
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
ETFs bought a net $79.8 million of Amgen stock in Wednesday's session.
Detailed price information for Amgen Inc (AMGN-Q) from The Globe and Mail including charting and trades.
Six growth drivers now account for 70% of product sales as guidance was raised.
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Detailed price information for Amgen Inc (AMGN-Q) from The Globe and Mail including charting and trades.
Detailed price information for Amgen Inc (AMGN-Q) from The Globe and Mail including charting and trades.
Amgen Inc (AMGN) lifted its 2026 revenue and EPS outlook as six key growth drivers surged 27%, offsetting a TEPEZZA decline and pending MariTide data.
This is the newest page. Registered accounts read further back.